Literature DB >> 1595522

The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty.

T F McGarry1, R S Gottlieb, J Morganroth, S L Zelenkofske, H Kasparian, P R Duca, R M Lester, T H Kreulen.   

Abstract

The degree of anticoagulation and its effect on the frequency of abrupt coronary artery closure, coronary ischemia, bleeding complications requiring transfusion, and death were examined in 336 patients after elective percutaneous transluminal coronary angioplasty (PTCA). All patients received a bolus of 10,000 U of heparin at the beginning of the procedure followed by a continuous infusion of 2000 U/hr. At the conclusion of the procedure the infusion was reduced to 1000 U/hr and continued for 18 to 24 hours at which time the heparin infusion was suspended to allow removal of arterial and venous access sheaths. Partial thromboplastin time (PTT) was examined while patients continued to receive the heparin infusion. There was a variable degree of PTT prolongation in response to a standard dose of heparin with a range of 34 seconds to "greater than 150 seconds." Patients were divided into two groups according to the degree of heparin-induced PTT prolongation: group A included 271 patients with PTT greater than or equal to 3 times the control value, and group B comprised 65 patients with PTT less than 3 times the control value. Ischemic complications were analyzed on day 1 after PTCA and at hospital discharge. Bleeding complications and mortality were examined only at hospital discharge. There was a significant reduction in the incidence of abrupt coronary artery closure in group A on day 1 (1.5% vs 10.7%, p less than 0.001) and at hospital discharge (2.6% vs 10.7%, p less than 0.003).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1595522     DOI: 10.1016/0002-8703(92)90793-u

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Safety of low dose heparin in elective coronary angioplasty.

Authors:  K T Koch; J J Piek; R J de Winter; G K David; K Mulder; J G Tijssen; K I Lie
Journal:  Heart       Date:  1997-06       Impact factor: 5.994

Review 2.  A guide to drug use during percutaneous coronary intervention.

Authors:  Joseph K Choo; John J Young; Dean J Kereiakes
Journal:  Drugs       Date:  2002       Impact factor: 9.546

3.  Heparin resistance in acute coronary syndromes.

Authors:  Jonathan D Rich; John M Maraganore; Edward Young; Rosa-Maria Lidon; Burt Adelman; Paul Bourdon; Supoat Charenkavanich; Jack Hirsh; Pierre Theroux; Christopher P Cannon
Journal:  J Thromb Thrombolysis       Date:  2007-01-13       Impact factor: 2.300

4.  Ticlopidine and aspirin interactions.

Authors:  L Gregorini; J Marco
Journal:  Heart       Date:  1997-01       Impact factor: 5.994

Review 5.  Low molecular weight heparin therapy for percutaneous coronary intervention: a practice in evolution.

Authors:  J K Choo; D J Kereiakes
Journal:  J Thromb Thrombolysis       Date:  2001-05       Impact factor: 2.300

Review 6.  The arterial thrombotic process and emerging drugs for its control.

Authors:  J M Maraganore
Journal:  Tex Heart Inst J       Date:  1993
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.